TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

ANDOVER, Mass., May 30, 2023 /PRNewswire/ — TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure,¬†today announced that on May 24, 2023, TransMedics granted non-qualified stock options to purchase an aggregate of 87,472 shares of its common stock and … Read more